About: Antiviral activity of selected antimicrobial peptides against vaccinia virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antiviral activity of selected antimicrobial peptides against vaccinia virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antiviral activity of selected antimicrobial peptides against vaccinia virus
Creator	Mohan, Ketha Atreya, Rao, Chintamani Shilpakala, Sainath
Source	Elsevier; Medline; PMC
abstract	Abstract Antimicrobial peptides (AMPs) are gaining importance as effective therapeutic alternatives to conventional antibiotics. Recently we have shown that a set of nine synthetic antimicrobial peptides, four originating from thrombin-induced human platelet-derived antimicrobial proteins named PD1–PD4 and five synthetic repeats of arginine-tryptophan (RW) repeats (RW1-5) demonstrate antibacterial activity in plasma and platelets. Using WR strain of vaccinia virus (VV) as a model virus for enveloped virus in the present study, we tested the same nine synthetic peptides for their antiviral activity. A cell culture-based standard plaque reduction assay was utilized to estimate antiviral effectiveness of the peptides. Our analysis revealed that peptides PD3, PD4, and RW3 were virucidal against VV with PD3 demonstrating the highest antiviral activity of 100-fold reduction in viral titers, whereas, PD4 and RW3 peptide treatments resulted in 10–30-fold reduction. The EC50 values of PD3, PD4 and RW3 were found to be 40μg/ml, 50μg/ml and 6.5μM, respectively. In VV-spiked plasma samples, the virucidal activity of PD3, PD4 and RW3 was close to 100% (90–100-fold reduction). Overall, the present study constitutes a new proof-of-concept in developing peptide therapeutics for vaccinia virus infections in biothreat scenarios and as in vitro viral reduction agents.
has issue date	2010-06-30(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2010.03.012
bibo:pmid	20347875
has license	els-covid
sha1sum (hex)	4619dafe309d4e28cc25e008d2b608ffd4c65d39
schema:url	https://doi.org/10.1016/j.antiviral.2010.03.012
resource representing a document's title	Antiviral activity of selected antimicrobial peptides against vaccinia virus
has PubMed Central identifier	PMC7114312
has PubMed identifier	20347875
schema:publication	Antiviral Research
resource representing a document's body	covid:4619dafe309d4e28cc25e008d2b608ffd4c65d39#body_text
is schema:about of	named entity 'ANTIMICROBIAL' named entity 'human' named entity 'reduction' named entity 'synthetic' named entity 'developing' named entity 'enveloped virus' named entity 'virucidal' named entity 'peptides' named entity 'vaccinia virus' named entity 'ANTIBIOTICS' named entity 'THEIR' named entity 'SYNTHETIC PEPTIDES' named entity 'ANALYSIS' named entity 'STRAIN' named entity 'ANTIVIRAL ACTIVITY' named entity 'OVERALL' named entity 'CONCEPT' named entity 'PRESENT' named entity 'HAVE' named entity 'ARGININE' named entity 'TRYPTOPHAN' named entity 'CLOSE TO' named entity 'NAMED' named entity 'FOLD' named entity 'TREATMENTS' covid:arg/4619dafe309d4e28cc25e008d2b608ffd4c65d39 named entity 'REPEATS' named entity 'OF-' named entity 'SELECTED' named entity 'ANTIVIRAL ACTIVITY' named entity 'VACCINIA VIRUS' named entity '40 G' named entity 'IN VITRO' named entity 'ESTIMATE' named entity 'PEPTIDE' named entity 'VACCINIA VIRUS' named entity 'VALUES' named entity 'STANDARD' named entity 'EFFECTIVENESS' named entity 'SCENARIOS' named entity 'PROTEINS' named entity 'SET' named entity 'HUMAN' named entity 'PEPTIDES' named entity 'ANTIMICROBIAL' named entity 'DEVELOPING' named entity 'EFFECTIVE' named entity 'PLAQUE' named entity 'PLASMA' named entity 'RECENTLY' named entity 'SAMPLES' named entity 'VIRUS' named entity 'PLATELETS' named entity 'VIRAL' named entity '100' named entity 'OUR' named entity 'CONVENTIONAL' named entity 'PD1' named entity 'HIGHEST' named entity 'GAINING' named entity 'MODEL' named entity 'DERIVED' named entity '100%' named entity 'ASSAY' named entity 'A CELL' named entity 'STUDY' named entity 'THERAPEUTIC' named entity 'THROMBIN' named entity '6.5' named entity 'ANTIBACTERIAL' named entity 'PROOF' named entity 'REDUCTION' named entity 'USING' named entity 'TESTED' named entity 'SYNTHETIC' named entity 'INDUCED' named entity 'NEW' named entity 'INFECTIONS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software